Jason Bock and Paul Wotton

Jason Bock, Ph.D., co-founder and CEO of CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is an accomplished leader with 20+ years of innovative biologics development and commercialization experience. Based in Houston, TX, CTMC was conceived to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Anderson’s clinical trial capabilities. Dr. Bock previously held leadership positions at MD Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences. Dr. Bock earned a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Molecular and Cellular Physiology from the Stanford University School of Medicine.

Paul K. Wotton, Ph.D. is the Executive Director of the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University’s health and medical technology discoveries into cures. He leverages his significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL), Cynata Therapeutics (ASC: CYP), Kytopen (Chairman), Combined Therapeutics and is a Co-Founder and Director of Avenge Bio, a clinical stage biotechnology company. Dr. Wotton was President and CEO of Ocata Therapeutics (NASDAQ: OCAT) until its acquisition by AstellasPharma in 2016.